{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"275"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"description":"The recommended Phase 2 dose for LY2603618 when administered approximately 24 hours after pemetrexed and cisplatin was based on the maximum tolerated dose (MTD) and achievement of predefined LY2603618 plasma systemic exposures targets (area under the LY2603618 plasma concentration versus time curve from time zero to infinity \\[AUC(0-∞)\\] \\>21,000 nanogram\\*hour/milliliter \\[ng\\*h/mL\\] and maximum LY2603618 plasma concentration \\[Cmax\\] \\>2000 nanograms/milliliter \\[ng/mL\\]).","groups":[{"description":"Cycles 1-2 (21-day cycle):\n\nDay 1: pemetrexed 500 mg/m\\^2 + cisplatin 75 mg/m\\^2\n\nDay 2: LY2603618 130 to 275 mg\n\nAfter 2 cycles, participants may have continued on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion was met.\n\nPemetrexed, cisplatin, and LY2603618 were administered IV over 10 minutes, 1 hour, and 1 hour, respectively.","id":"OG000","title":"Phase 1: Pemetrexed + Cisplatin + LY2603618"}],"paramType":"NUMBER","populationDescription":"Phase 1 participants who received at least 1 dose of any of the study drugs.","reportingStatus":"POSTED","timeFrame":"Time of first dose to last dose","title":"Phase 1: Recommended Phase 2 Dose of LY2603618","type":"PRIMARY","unitOfMeasure":"mg"}